NGEN — Nervgen Pharma Share Price
0.000.00%
Last trade - 00:00- CA$211.56m
- CA$194.39m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 82.11 | ||
| Price to Tang. Book | 100.18 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -964.49% | ||
| Return on Equity | -8460.23% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.
Directors
- William Radvak CHM (56)
- Paul Brennan PRE
- Amy Franke VOP
- Michael Abrams IND (62)
- Brian Bayley IND (65)
- Harold Punnett IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 19th, 2017
- Public Since
- March 13th, 2019
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 71,230,849
- Address
- 112-970 Burrard Street, Unit 1290, VANCOUVER, V6Z 2R4
- Web
- https://www.nervgen.com/
- Phone
- +1 7787311711
- Auditors
- KPMG LLP
Upcoming Events for NGEN
NervGen Pharma Corp Annual Shareholders Meeting
Q1 2025 NervGen Pharma Corp Earnings Release
NervGen Pharma Corp Annual Shareholders Meeting
Q2 2025 NervGen Pharma Corp Earnings Release
Similar to NGEN
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
FAQ
What is the Nervgen Pharma share price?
As of Today at 04:14 UTC, shares in Nervgen Pharma are trading at CA$2.97. This share price information is delayed by 15 minutes.
How has the Nervgen Pharma share price performed this year?
Shares in Nervgen Pharma last closed at CA$2.97 and the price had moved by +46.04% over the past 365 days. In terms of relative price strength the Nervgen Pharma share price has outperformed the Toronto Stock Exchange 300 Composite Index by +29.84% over the past year.
What are the analyst and broker recommendations for Nervgen Pharma?
The overall consensus recommendation for Nervgen Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Nervgen Pharma dividend yield?
Nervgen Pharma does not currently pay a dividend.
Does Nervgen Pharma pay a dividend?
Nervgen Pharma does not currently pay a dividend.
When does Nervgen Pharma next pay dividends?
Nervgen Pharma does not currently pay a dividend.
How do I buy Nervgen Pharma shares?
To buy shares in Nervgen Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nervgen Pharma?
As of the previous close price of CA$2.97, shares in Nervgen Pharma had a market capitalisation of CA$211.56m.
Where are Nervgen Pharma shares listed?
Here are the trading details for Nervgen Pharma:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: NGEN
What kind of share is Nervgen Pharma?
Based on an overall assessment of its quality, value and momentum Nervgen Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nervgen Pharma share price forecast for 2025?
The analyst consensus target price for shares in Nervgen Pharma is CA$4.97. That is 67.34% above the last closing price of CA$2.97.
Analysts covering Nervgen Pharma currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.36 for the next financial year.
Find out moreWhat is the trend in the Nervgen Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nervgen Pharma. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +7.82%.
As of the last closing price of CA$2.97, shares in Nervgen Pharma were trading +7.42% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nervgen Pharma PE Ratio?
The Nervgen Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$2.97.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nervgen Pharma?
Nervgen Pharma's management team is headed by:
- William Radvak - CHM
- Paul Brennan - PRE
- Amy Franke - VOP
- Michael Abrams - IND
- Brian Bayley - IND
- Harold Punnett - IND